In prostate cancer, ATM PVs may be either germline or somatic in origin, and are present in 5–8% of castration-resistant tumors overall; this is an enrichment of approximately two-fold over the frequency found in localized prostate cancers, suggesting an association between ATM PVs and aggressive disease [104,105,106]. This evidence concerns the gene ATM and prostate carcinoma.